Pfizer’s Allergan Acquisition Paves The Way For A Split – But Delayed
Executive Summary
Pfizer’s $160bn deal to buy Allergan and redomicile in Ireland could position the company better for an eventual split. But Pfizer said it will now wait until 2018 to decide if it will break up the company, disappointing some investors.
You may also be interested in...
Stronger Together: Pfizer Decides Against A Split
The pharma giant's decision not to break up into two separate publicly traded companies as it has been contemplating for several years reflects an improved growth outlook and the inability to unlock trapped value. Now Pfizer can finally get on with business.
With Winrevair Approved, Merck Has A Chance To Execute On CV Strategy
The activin signaling inhibitor sotatercept was approved by the US FDA for pulmonary arterial hypertension.
CinFina Pushes Early Work In Obesity In Hopes Of A Deal
Emerging Company Profile: CinFina is advancing two novel mechanisms of action in obesity as monotherapies and in combination with GLP-1s.